14 Nov

HealthBeacon signs agreement with Canada’s leading patient support provider, Innomar Strategies

HealthBeacon, partners with Innomar Strategies, to bring its smart sharps bin offering to Canada.

(DUBLIN, IE., TORONTO, ON. –November 14th, 2018) HealthBeacon announced today their partnership with Innomar Strategies to provide the HealthBeacon smart sharps bin and digital therapeutic platform to Canadian patients across the country.

HealthBeacon is a Dublin headquartered, digital therapeutic company that produces a smart sharps bin to track and drive medication adherence. Following their recent FDA clearance in the US, HealthBeacon has begun investing resources in the North American markets of the United States and Canada. Innomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market, helping patients navigate the complicated Canadian healthcare system, and providing support for their injections and infusions.

“We have seen great patient engagement with the HealthBeacon tool in Ireland. It has been instrumental in aiding us in identifying patients that need assistance, and helping drive adherence to their medication. I’m delighted to see they are making HealthBeacon available in Canada.” – Dr. Trevor Duffy, Rheumatologist

HealthBeacon began operations in Canada with the opening of their Montreal office in December 2016. HealthBeacon CEO, Jim Joyce commented, The Canadian market is a large market, both geographically and in terms of patients who could benefit from our technology. The signing of this partnership is a major milestone in making our technology accessible to the Canadian market.

As an industry leader, Innomar deeply understands the patient journey.  A core focus is delivering best-in-class care and education through patient services to monitor adherence and ensure optimal outcomes.

“We look forward to partnering with HealthBeacon as they move into the Canadian market.  Our focus is on patient care, and having a tool to track and facilitate medication adherence brings value to patient care across Canada,” says Amar Pabla, Vice President Nursing, Clinics and Pharmacovigilance.

“HealthBeacon are a fantastic example of Irish innovation. This partnership is testimony to the deepening links between Irish and Canadian healthcare. As the government agency driving the growth of Irish businesses internationally, we at Enterprise Ireland look forward to seeing HealthBeacon support Innomar Strategies in its mission to advance patient support across Canada.” – Neil Cooney, Country Manager Canada, Enterprise Ireland

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. The HealthBeacon is a smart sharps bin for patients who self-inject medications at home. It is digitally connected and programmed with a patient’s personal medication schedule, and uses customized reminders to help them start and stay on track with medication. The company is headquartered in Dublin, Ireland and has offices in the US and in Canada. Learn more at www.healthbeacon.com

About Innomar Strategies

Innomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market. We deliver end-to-end commercialization solutions to improve product access, increase supply chain efficiency and enhance patient care. Strategic consulting, patient support programs, nursing and clinical services, and specialty pharmacy and logistics are just a few of our key areas of specialization. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment tobest-in-class care, Innomar Strategies helps navigate the patient journey to optimize health outcomes. Visit us at www.innomarstrategies.com.

31 Oct

HealthBeacon Builds Presence in Asia

HealthBeacon started off in Ireland piloting its technology with the local Irish divisions of pharmaceutical giants. These same great clients networked us into their global organisation which led to deployment of our HealthBeacon Medication Management technology across 10 Countries: USA, Canada, across the EU, South Africa, Baltics, Brazil, Israel and South Africa. We had to develop global organisational muscles early in our life, our clients made it a prerequisite. Now we are heading to Asia!

We will be featured on two panels at large Digital Health events in both Mumbai and Singapore.

The first will be a global gathering for HealthXL presented by Abbott and featuring panelists and speakers that include Arun Kumar, Head of South Asia for Bayer and Dr Arvind Sivaramakrishnan, Chief Information Officer at Apollo Hospitals

The second event is a panel about Digitising Patient Care featuring Jim Joyce, Everett Leonidas from Aviva Ventures which will be moderated by Susanna Hasenoehrl of Joice Nutrition and hosted by SG Innovate in Singapore.

In collaboration with these two great organisations, HealthXL and SG Innovate, we will begin  introducing ourselves and our technology into the Singapore, Australian and Indian markets. These three markets will become our first wave of Asia-Pac HealthBeacon deployments.

Operating a young technology company across 10 countries from our two office locations,  Dublin and Boston required us to leverage scaling technology platforms, find excellent local partners, build scalable roll-out processes that are all driven by a team that thinks globally.

 

HealthXL Global Gathering Mumbai

Date/Venue: 1st November 2018, 9:00am- 4:00pm

Bandra Kurla Complex Mumbai

Topics: 

  • Patient Centricity
  • Non-Communicable DiseaseDigital
  • Health Investments in India
  • Big Data to Improve Patient Outcomes

 

 

 

Digitising Patient Care- SG Innovate

Date/ Venue: 8th November 2018, 5:00pm- 7:00pm

32 Carpenter Street, Singapore 059911

In the midst of a patient data revolution, this panel will discuss the importance of caring for and facilitating patient data in a way that makes sense. Medtech and digital therapeutics are increasingly focused on patient centricity and care. Our leading experts will be focused on providing a vision for the future of patient care in a digital world.

 

 

27 Sep

HealthBeacon Opens New Production Facility

INNOVATIVE IRISH DIGITAL HEALTH COMPANY EXPANDS IRISH HEADQUARTERS

Today, Wednesday 26th September, Minister of State for Mental Health and Older People Jim Daly T.D. joined Irish digital health technology company HealthBeacon, to celebrate the official opening of their newly expanded Irish headquarters in Dublin 12.

HealthBeacon has been on an upward trajectory since founding in 2014, with 2018 their busiest year yet. Over the past four years the innovative Irish medtech company has experienced comprehensive market penetration within Ireland, witnessing in excess of 100% market growth.  HealthBeacon has doubled staffing over the last 18 months, now employing 30.  With offices in Ireland, Canada and the US, the business operates across 10 markets from the Headquarters in Dublin. The company was recently granted FDA (US Food and Drugs Administration) clearance and launched into the US market, which is worth hundreds of millions of dollars.

HealthBeacon develops smart tools for managing medication. The ‘Smart Sharps bin”, designed for injectable medication management, tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. The stand-alone device is bringing medtech into the ‘heart of the home’ helping to address one of the biggest unmet needs within the health arena – tracking patient’s real time usage and supporting chronic medicine schedules are maintained.

The expansion of HealthBeacon HQ makes way for advanced manufacturing processes and accommodate their growing data science team. The ground-breaking Irish company growth has been driven by global demand from the pharmaceutical industry and as such is increasing the technical capacity, customer care, warehouse and manufacturing space for both the production and the product development teams.

Speaking at the event, Jim Joyce, CEO of HealthBeacon added;

2018 has been a fast track year for HealthBeacon and today reflects our successes and our ongoing continued investment here in Ireland, our global HQ. The company has entered multiple new markets this year and received FDA clearance allowing us to enter the US market, with the world’s only Smart Sharps Adherence Platform. Looking forward, we are committed to continuing contributing to Ireland’s reputation as a global leader offering innovative best in class healthcare solutions.

The HealthBeacon system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into thousands of patients homes throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

HealthBeacon have worked closely with Enterprise Ireland since founding and were joined by Terence O’Rourke, Chairman, Enterprise Ireland today:

I am delighted to be at the opening of the HealthBeacon expanded production facility to support the company’s growth activities.  Working closely with Enterprise Ireland since 2014, HealthBeacon is designing and developing digital tools that impact positively on the lives of patients worldwide.

 The thriving Irish medtech sector continues its story of success and the development of innovative products such as the Smart Sharp Bin contribute significantly to Ireland’s reputation as a global leader in healthcare solutions. Our aim at Enterprise Ireland is to help businesses with global ambition to build scale and expand reach, and we will continue to work with HealthBeacon as it delivers medical solutions through innovation, underpinning the company’s continued growth in world markets.”

The opening event was attended by leaders from; medtech sector, executives from healthcare, pharmaceuticals, technology and finance.

Speaking before the launch, Minister for Health Simon Harris TD said; “Health research and innovation are an integral part of a well- functioning health service. Medical progress is directly linked to a strong health research community. We recognise that health research is a key factor in promoting the health of the population, combating disease, reducing disability and improving the quality of care. It can and does improve the quality of our health services and the quality of life of many in our society. It can do this by utilising research-led preventative strategies and deployment of services; by bringing the latest treatments to patients; by developing new models of care, and improving the efficiency and effectiveness of health care delivery.” 

Keynote speakers at the event who provided expertise on scaling healthcare technology companies in Ireland, included; Jim Joyce, CEO of HealthBeacon, Terence O’Rourke, Chairman of Enterprise Ireland, and Orla O’Gorman, Head of Equity Listing Ireland, EURONEXT.

17 Sep

HealthBeacon joins Irish Trade Mission in Brazil

Digital Therapeutic company, HealthBeacon, joined Irish and Brazilian Ministers for trade mission in São Paulo.

HealthBeacon joined Enterprise Ireland last week in São Paulo, Brazil with Irish Minister Pat Breen TD, Minister of State for Trade, Employment, Business, the EU Digital Single Market and Data Protection as part of a trade mission to Brazil. HealthBeacon and Minister Breen were hosted by AbbVie Pharmaceuticals at a working lunch with the key Brazilian government bodies in Education and Research as well as meeting with Brazil’s Minister of Science, Technology and Innovation, Mr. Gilberto Kassab. The Minister met with LATAM General Manager, Andrea Rangel, and North American Operations Director, Sean Glynn.

HealthBeacon has received full regulatory approval from Anatel and Anvisa to bring their smart sharps system into the Brazilian market. Brazil is a major market with millions of patients and is a key country in HealthBeacon’s global expansion strategy.  The Brazil launch will represent the first market in South America with additional LATAM markets implementing shortly.

Enterprise Ireland will be hosting this trade mission focusing on Irish trade in Brazil and Latin America.  Ireland is a proven innovation powerhouse, ranked a European leader for innovation in SMEs, employment impacts and sales impacts by the 2018 European Innovation Scoreboard:

  • Ireland is rated by Bloomberg as one of the top 15 most innovative nations in the world
  • Ireland ranks 11th globally for quality of its scientific research (Thomsson Reuters/Clarivate InCites, November 2017)
  • Ireland ranks 6th in the IMD World Competitiveness ranking
  • Ireland ranks 8th in Forbes Best Countries for Business ranking

 

Two-way trade between Ireland and Brazil continues to grow, with the combined trade in goods and services worth close to €1.8 billion in 2016. Irish Small and Medium Enterprises, such as those on this trade mission, have been shown a strong commitment to developing partnerships in the Brazilian market, increasing their sales here to over €42 million in 2017. 

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

10 Sep

HealthBeacon shortlisted as Supplier of the Year to the Pharma Industry

Digital Therapeutics company, HealthBeacon has been short listed in two categories at the Pharma Industry Awards.

The HealthBeacon Smart Sharps Platform has once again been nominated for their outstanding work with global pharmaceutical brands to support injectable medication treatments. HealthBeacon will defend their title of Pharma Project of the Year at the Pharma Industry Awards 2018. This year, HealthBeacon has also been short listed for another important award, Pharma Supplier of the Year. The Supplier of the Year award recognises a company or organisation that has provided a ‘best in class’ service, solution, product or goods to the Pharmaceutical industry. So far in 2018, HealthBeacon has received FDA clearance to enter the USA market, regulatory approval to bring HealthBeacon to Brazil and won multiple awards from the pharmaceutical industry.

Last year, HealthBeacon won the category for Pharma Project of the Year-Large and were shortlisted for Innovation of the Year. Since launching in 2014, the Pharma Industry Awards has established itself as the benchmark for excellence for those operating in Ireland’s pharma industry.

The Pharma Project of the Year award recognises an outstanding project undertaken in Ireland’s Pharma industry over the past 12 months. We believe the HealthBeacon project has received this special recognition due to the scale of the opportunity to impact the pharmaceutical industry. With billions of dollars spent annually, medication adherence is one of the most challenging issues facing the industry today.

The finalists will be present and the winners will be revealed at the gala awards ceremony on October 23rd at the Clayton Hotel Burlington Road, Dublin.

https://www.pharmaawards.ie/shortlist

 

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

09 Jul

HealthBeacon announces the US Launch of its FDA Cleared Adherence Device at MAGIC Foundation’s Annual Conference in Chicago



HealthBeacon partners with MAGIC Foundation to bring their innovative digital therapeutic technology to US patient group for human growth disorders.

(Dublin, Ireland; Chicago, IL, July 9th, 2018) HealthBeacon, a digital therapeutic leader in medication adherence, and the MAGIC Foundation, the world’s leading advocacy and information group for human growth disorders, has announced that their smart sharps platform will be made available to patients that are members of the MAGIC Foundation in the USA.

The MAGIC Foundation is a charitable non-profit organization created to provide support services for the families of children afflicted with a wide variety of chronic and/or critical disorders, syndromes and diseases that affect a child’s growth. HealthBeacon identified the MAGIC Foundation as their chosen partner to promote the MAGIC Foundation mission “to reduce the emotional and physical trauma caused by growth disorders, resulting in healthier, happier children and consequently, adults.”

HealthBeacon will be introduced to patients and carers at the MAGIC Foundation’s 24th Annual Conference in Illinois on July 12th, 2018. HealthBeacon’s injectable adherence platform has been cleared by the FDA, and this cornerstone event is the first step to make the HealthBeacon smart sharps system available to the millions of Americans on long term, chronic injectable care. This major launch event will kick off HealthBeacon’s US Tour to introduce their digital therapeutic platform to influencers and advocates nationwide.

MAGIC Foundation is the global leader in endocrine health, advocacy, education, and support. HealthBeacon believes that engaging with the world leading advocacy groups will provide a strong network and patient engagement program to improve medication adherence for patients with human growth disorders.

“MAGIC Foundation is so pleased to offer our patients such an impactful and innovative solution to help with their treatment programs.  We appreciate and always welcome ways to improve the lives and the care of our patients and their families.” Dianne Kremidas, Executive Director at The MAGIC Foundation.

Since launching commercially in Europe, in 2013, HealthBeacon currently serves thousands of patients across 10 markets in Canada, Europe, the Middle East and South America.

About HealthBeacon
HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

About MAGIC Foundation
The MAGIC Foundation was incorporated in the state of Illinois and received 501(C)3 non-profit status October 29, 1989. Since its inception the Foundation has grown to include support services for adults who were also impacted by these disorders.

24 May

HealthBeacon Obtains FDA Clearance for the World’s First Smart Sharps Adherence Device



Digital Therapeutic company HealthBeacon receives 510K FDA clearance to provide smart sharps bins to US patients

(Dublin, Ireland; Boston, MA) HealthBeacon, a digital therapeutic innovator, announced today that they have received clearance by the United States Food and Drug Administration (FDA) to offer the HealthBeacon smart sharps bin to patients using injectable medications in the US.

HealthBeacon’s injectable adherence platform has been cleared by the FDA, and will be available for the first time to the millions of Americans on long term, chronic injectable care. HealthBeacon anticipates the US commercial launch of its platform later this summer.

Since launching commercially in Europe, in 2013, HealthBeacon currently serves thousands of patients across 10 markets in Canada, Europe, the Middle East and South America.

HealthBeacon CEO, Jim Joyce, has stated, “Working with the FDA over the last year, and ultimately receiving FDA clearance is a defining moment for HealthBeacon as a company. We are excited to launch in the US later this summer.”

The digital therapeutic market has reached significant landmarks in the last year, and HealthBeacon joins a small but elite number of digital therapeutic organizations with validated technology that have received FDA clearance.

Robert K. Coughlin, President and CEO of MassBio has commented, “I am delighted to hear HealthBeacon has received FDA Clearance for their novel medical technology, and has chosen Boston to launch their U.S. operations. There is no better place in the world for the life sciences, and we’re thrilled to welcome a company that will bring further value to the healthcare system and to patients.”

Dublin, Ireland based HealthBeacon has strong ties to the US, as it is founded by Irish-American and native Bostonian Jim Joyce. This connection has strengthened since opening their first US based office in Boston in March of 2017.

This clearance is part of HealthBeacon’s regulatory strategy to make its technology available globally. This follows on HealthBeacon’s recent announcement of approval for the Brazilian market.

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

12 Apr

Digital Therapeutic Innovator HealthBeacon receives full regulatory approval for the Brazilian market

(DUBLIN, SAO PAOLO, April 12, 2018) HealthBeacon announced today that it has completed the regulatory process to launch their smart sharps bin and digital therapeutic platform into Brazil. Approval for marketing by both the telecom and health regulators opens HealthBeacon to service the millions of patients on injectable medications in Brazil. Following great success in Europe and North America, HealthBeacon’s Brazilian partners are enthusiastic about presenting this innovative technology through their patient support programmes.

HealthBeacon is the market leader in tracking adherence for injectable medications and has already launched into 8 countries in Europe and North America. Thousands of patients in these markets are showing double digit increases in adherence versus patients without connected medicines.

Due to the size of Brazil, supporting patients who are far away from hospital is a key priority in improving outcomes of community health. HealthBeacon entering this market represents an advancement in care for patients on chronic injection therapies used in the home. HealthBeacon CEO Jim Joyce said about the launch in Brazil,

“We’ve been working on preparing for the Brazilian market over the last year. Our strategy is to make our technology available globally we are excited to make the HealthBeacon available in such an important market.”

Back in October, HealthBeacon hosted Brazilian insurance influencers in our Dublin office to participate in a workshop to explore the opportunities afford in Brazil and the enthusiasm was resounding.

Brazil is a major market with millions of patients and is a key country in HealthBeacon’s global expansion strategy.  The Brazil launch will represent the first market in Latin America with additional LATAM markets implementing shortly. HealthBeacon’s global expansion includes entering another 8 countries across Europe, North America and Latin America in 2018.

The Latin American team is headed up by Regional Manager Andrea Rangel, based in Sao Paulo, Brazil. The HealthBeacon will be available to patients in Brazil over the coming months.

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

|

(DUBLIN, SÃO PAULO, 12 de abril de 2018) HealthBeacon anunciou hoje que concluiu o processo de regulamentação para o lançamento de sua plataforma terapêutica inteligente e digital no Brasil. A aprovação para comercialização pelos reguladores de telecomunicações e de saúde abre o HealthBeacon para atender aos milhões de pacientes com medicamentos injetáveis ​​no Brasil. Após o grande sucesso na Europa e na América do Norte, os parceiros brasileiros da HealthBeacon estão entusiasmados em apresentar essa tecnologia inovadora por meio de seus programas de suporte ao paciente.

A HealthBeacon é líder de mercado no rastreamento da adesão de medicamentos injetáveis ​​e já foi lançada em oito países da Europa e América do Norte. Milhares de pacientes nesses mercados tem apresentando aumentos de dois dígitos na adesão versus pacientes sem medicamentos conectados.

Devido ao tamanho do Brasil, o suporte a pacientes que estão longe do hospital é uma prioridade fundamental para melhorar os resultados da saúde da comunidade. A entrada da HealthBeacon neste mercado representa um avanço no atendimento aos pacientes em terapias de injeção crônica utilizados em casa. O CEO da HealthBeacon, Jim Joyce, falou sobre o lançamento no Brasil,

“Estamos trabalhando na preparação para o mercado brasileiro desde o ano passado. Nossa estratégia é disponibilizar nossa tecnologia globalmente e estamos empolgados em disponibilizar o HealthBeacon em um mercado tão importante”.

Em outubro, a HealthBeacon trouxeos influenciadores de seguros brasileiros em nosso escritório em Dublin para participar de um workshop para explorar as oportunidades oferecidas no Brasil e o entusiasmo foi retumbante.

O Brasil é um mercado importante com milhões de pacientes e é um país-chave na estratégia de expansão global da HealthBeacon. O lançamento no Brasil representará o primeiro mercado na América Latina com mercados adicionais LATAM implementando em breve. A expansão global da HealthBeacon inclui a entrada em outros 8 países da Europa, América do Norte, América Latina e África em 2018.

A equipe da América Latina é liderada pela Gerente Regional Andrea Rangel, com sede em São Paulo, Brasil. O HealthBeacon estará disponível para pacientes no Brasil nos próximos meses.

Sobre o HealthBeacon

HealthBeacon é uma empresa de terapêutica digital que desenvolve ferramentas inteligentes para gerenciar medicamentos. A HealthBeacon desenvolveu um sistema de gerenciamento de medicação injetável que monitora os pacientes digitalmente, mantendo-os aderentes às suas prescrições e aproveitando os dados em tempo real para conduzir a intervenção clínica. Esse sistema foi revisado clinicamente, validado pela indústria farmacêutica e integrado a programas de atendimento ao paciente na América do Norte e na Europa, fornecendo dados valiosos para o paciente e sua equipe clínica.

26 Mar

A “Device” For Providing Better Drug Outcomes

HealthBeacon CEO, Jim Joyce was recently interviewed by Bob Marshall, Chief Editor of digital publication, Med Device Online. The interview was featured in the publication highlighting medication adherence issues, and the approach HealthBeacon is taking to reduce medication-related problems. Using data from the Mayo Clinic and the American Journal of Managed Care, Marshall identifies HealthBeacon’s approach to real-world evidence and patient experience.

Read the full article here.

20 Mar

HealthBeacon Announces Winning of Johnson & Johnson Innovation, JLABS Patient Adherence QuickFire Challenge

(Dublin, New York, March 19th, 2018) HealthBeacon announces that is has been chosen as the winner of the Johnson & Johnson Innovation, JLABS and Janssen Supply Chain Group, LLC (JSC) Patient Adherence QuickFire Challenge. The announcement was made at the New York Genome Center, home to the new JLABS @ NYC opening in June 2018, in New York, NY, USA. This challenge was designed to identify companies that are creating innovative solutions for patients, that are easy to use and may be integrated into a patient’s typical daily healthcare routine. HealthBeacon was voted as the overall winner of the challenge and as such will receive a $75,000 award.

HealthBeacon was identified as the winner for displaying excellence in the following categories.

  • High impact on healthcare outcomes and adherence
  • Leap frog innovation & market competitiveness: new methodology & technology feasibility
  • User friendly & ease of implementation
  • Integrated, holistic solution from Pharma manufacturer to patient
  • Commercial scalability

 

HealthBeacon has a strong understanding of how adherence solutions can be used to improve patient outcomes. HealthBeacon was represented at the event by CTO and Co-Founder Kieran Daly, and Design Director, Kyle Bolton.

About HealthBeacon

HealthBeacon is a Digital Therapeutics company that develops smart tools for managing medication. HealthBeacon has developed an injectable medication management system that tightly monitors patients digitally, keeping them adherent to their prescription and leveraging real time data to drive clinical intervention. This system has been clinically reviewed, validated by the pharmaceutical industry and has been integrated into patient care programs throughout North America and Europe, delivering valuable data to both the patient and their clinical team.

© 2015 Health Beacon - Privacy Policy - Website by Medusa